Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 13/20 | 0.45 |
| ▸ | RARA | P10276 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14508184 | 1.00 | MEN1 (0.52) | MEN1RAB9AKMT2APDK2RARA | |
| SCHEMBL14508277 | 1.00 | MEN1 (0.52) | MEN1RAB9AKMT2APDK2RARA | |
| SCHEMBL14508174 | 0.98 | MEN1 (0.53) | MEN1RAB9AKMT2APDK2RARA | |
| SCHEMBL19885773 | 0.94 | PDK2 (0.48) | MEN1RAB9AKMT2APDK2RARA | |
| SCHEMBL14425535 | 0.91 | KMT2A (0.44) | MEN1RAB9AKMT2APDK2RARA | |
| SCHEMBL14425900 | 0.91 | KMT2A (0.44) | MEN1RAB9AKMT2APDK2RARA | |
| SCHEMBL19885793 | 0.91 | KMT2A (0.44) | MEN1RAB9AKMT2APDK2RARA | |
| SCHEMBL14425877 | 0.91 | KMT2A (0.44) | MEN1RAB9AKMT2APDK2RARA | |
| SCHEMBL19885805 | 0.91 | KMT2A (0.44) | MEN1RAB9AKMT2APDK2RARA | |
| SCHEMBL14425534 | 0.89 | MEN1 (0.45) | MEN1RAB9AKMT2APDK2RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070122652-A1 | Compound and organic electroluminescent device using same | CANON KABUSHIKI KAISHA (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20070122652-A1 | Compound and organic electroluminescent device using same | CANON KABUSHIKI KAISHA (JP) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070122652-A1 | Compound and organic electroluminescent device using same | OR10J3, LEF1, RPL19 | MEN1 985/4885RAB9A 591/4885KMT2A 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.